{"id":8478,"date":"2020-07-24T10:08:05","date_gmt":"2020-07-24T17:08:05","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8478"},"modified":"2021-04-05T10:09:32","modified_gmt":"2021-04-05T17:09:32","slug":"immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19-vaccine-in-healthy-adults-aged-18-years-or-older-a-randomised-double-blind-placebo-controlled-phase-2-trial","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/24\/immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19-vaccine-in-healthy-adults-aged-18-years-or-older-a-randomised-double-blind-placebo-controlled-phase-2-trial\/","title":{"rendered":"Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A\u00a0Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial"},"content":{"rendered":"<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"43\" data-aria-posinset=\"2\" data-aria-level=\"1\"><span data-contrast=\"auto\">Zhu et al. report\u00a0<\/span><span data-contrast=\"auto\">findings from a p<\/span><span data-contrast=\"auto\">hase 2 randomized, double-blind, placebo-controlled single-center (Wuhan) trial of an Ad5-vecctored COVID-19 vaccine.\u00a0<\/span><span data-contrast=\"auto\">A total of\u00a0<\/span><span data-contrast=\"auto\">508 participants were randomly assigned to treatment (n=253 low dose, n=129 medium dose) or placebo (n=126; vaccine excipients with no viral particles). Both treatment groups had high seroconversion rates by 28 days (96% in the low dose group and 97% in the high dose group) and demonstrated significant neutralizing antibody responses, as well as significant T-cell responses. Adverse reactions were reported in 72% and 74% of the low- and high-dose treatment arms, versus 9% of the placebo arm, all of which were self-limiting and resolved within 72-96 hours without medication<\/span><span data-contrast=\"auto\">.<\/span><span data-contrast=\"auto\">\u00a0No serious adverse reactions were documented within 28 days.\u00a0<\/span><span data-ccp-props=\"{&quot;134233279&quot;:true,&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><i><span data-contrast=\"none\">Zhu et al. (July 2020). Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A\u00a0Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial.\u00a0<\/span><\/i><i><span data-contrast=\"none\">The\u00a0<\/span><\/i><i><span data-contrast=\"none\">Lancet.\u00a0<\/span><\/i><a href=\"https:\/\/doi.org\/10.1016\/S0140-6736(20)31605-6\"><span data-contrast=\"none\">https:\/\/doi.org\/10.1016\/S0140-6736(20)31605-6<\/span><\/a><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559685&quot;:720,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zhu et al. report\u00a0findings from a phase 2 randomized, double-blind, placebo-controlled single-center (Wuhan) trial of an Ad5-vecctored COVID-19 vaccine.\u00a0A total of\u00a0508 participants were randomly assigned to treatment (n=253 low dose, n=129 medium dose) or placebo (n=126; vaccine excipients with no viral particles). Both treatment groups had high seroconversion rates by 28 days (96% in the&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2020\/07\/24\/immunogenicity-and-safety-of-a-recombinant-adenovirus-type-5-vectored-covid-19-vaccine-in-healthy-adults-aged-18-years-or-older-a-randomised-double-blind-placebo-controlled-phase-2-trial\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[],"topic":[31],"class_list":["post-8478","post","type-post","status-publish","format-standard","hentry","category-article-summary","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8478"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8478\/revisions"}],"predecessor-version":[{"id":8479,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8478\/revisions\/8479"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8478"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}